Skip to main content
. 2023 Aug 17;16:147–167. doi: 10.2147/CEG.S375969

Figure 1.

Figure 1

Summary of select advanced therapy classes with current development status of associated agents.

Abbreviations: SC, subcutaneous; IL, interleukin; JAK, janus kinase; TYK2, tyrosine kinase 2; S1PR, sphingosine 1 phosphate receptor; TNF, tumor necrosis factor.